We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnostic Test Distinguishes Between Active and Latent Tuberculosis

By LabMedica International staff writers
Posted on 20 Apr 2011
An innovative blood test has been developed as an additional test to distinguish rapidly individuals with active tuberculosis (TB), and from these, those with latent TB infection. More...


By simply performing an extra blood test using a protein of the bacillus, Mycobacterium tuberculosis, named heparin-binding hemagglutinin adhesin (HBHA), it was possible to distinguish between those infected from those who have progressed to the pathological phase of the disease.

Scientists at the Catholic University of the Sacred Heart (Rome, Italy) developed the test in collaboration with others at the L. Spallanzani National Institute for Infectious Diseases (INMI; Rome, Italy). The team assayed the blood of 87 individuals at different stages of TB who scored positive with the QuantiFERON TB Gold In-Tube test (QFT-IT; Cellestis GmbH; Darmstadt, Germany). The QFT-IT blood test is an interferon-γ release assays (IGRA), based on the release of interferon-γ in response to M. tuberculosis-specific antigens, and is able to identify selectively those who have contracted TB infection.

In the study, the scientists developed an innovative diagnostic algorithm, which consists of a response to the protein HBHA in combination with the IGRA and the results have shown that the response to HBHA is associated with latent TB infection. This procedure allows the rapid identification those who really need the treatment for active TB. They showed that the lymphocyte T-cell response to a recombinant and methylated HBHA of M. tuberculosis produced in M. smegmatis--a nonpathogenic microorganism-- is useful to discriminate between active and nonactive TB disease among those responsive to QFT-IT in a whole blood system.

Stefania Zanetti, PhD, a professor of microbiology at the University of Sassari (Sassari, Italy), said," The response to HBHA can be used as a biomarkers for latent TB infection and then to some extent can be considered as a response of protection to TB. It is important to understand what are the mechanisms triggered by the infection which can cause the appearance or not of the disease.” The study was published online on March 29, 2011, in the Public Library of Science journal PLoS ONE.

Related Links:
Catholic University of the Sacred Heart
Italian National Institute for Infectious Diseases
Cellestis
University of Sassari




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.